印度尼西亚Moewardi博士医院IV期结直肠腺癌患者的肿瘤大小和癌胚抗原（CEA）水平之间的关系

Rakhmawati Eri¹, Sulistyani Kusumaningrum¹, Widiastuti ¹, Prasetyo Putro¹, Hari Wujoso², Ida ³
1、Moewardi博士医院放射科/ Sebelas Maret大学医学系
2、Moewardi博士医院法医部/ Sebelas Maret大学医学系
3、Moewardi博士医院医学外科部/ Sebelas Maret大学医学系

摘要

背景：根据组织病理学，结直肠腺癌是最常见的结直肠癌类型之一，约占全世界每年诊断的癌症病例的10%。肿瘤的大小和癌胚抗原（CEA）的水平被用来确定结直肠癌的存在及对其进行评价。然而，在印度尼西亚人口中，基于腹部CT增强扫描的结直肠癌大小与CEA水平之间的相关性研究仍然非常少。本研究旨在分析IV期结直肠腺癌患者腹部CT增强扫描检查的肿瘤大小与癌胚抗原（CEA）水平之间的关系。受试者和方法：2021年2月至2021年7月，在苏拉卡尔塔Moewardi博士医院放射科进行了一项横断面研究。本研究共选取了40名IV期结直肠腺癌患者。患者已经有了血液CEA水平的检查结果，并进行了腹部CT增强扫描。因变量是血液CEA水平。自变量是肿瘤大小。数据从医疗记录中收集，并通过Spearman检验进行分析。结果：肿瘤大小和CEA水平之间存在着积极和显著的关系（r=0.47；p=0.003）。结论：肿瘤大小与IV期结直肠腺癌患者的血液CEA水平呈正相关。

关键词

结直肠腺癌；腹部CT增强扫描；癌胚抗原（CEA）

参考

[1] American Cancer Society. 2018. What is colorectal cancer?. Accessed from https://www.cancer.org/cancer/kolon-rectal-cancer/about/

what-is-colorectalcancer.html.

[2] Amersi F, Agustin M, Ko CY (2005). Colorectal cancer: epidemiology, risk fac-tors, and health services. Clin Kolon Rectal Surg. 18(3): 133-140. https://dx.doi.org/10.1055%2Fs-2005-916274.

[3] Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66(4): 683-691. https://doi.org/10.1136/gutjnl-2015-310912.

[4] [Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6): 394-424. https://doi.org/10.3322/caac.21492.

[5] Bohorquez M, Sahasrabudhe R, Criollo A, Sanabria-Salas MC, Vélez A, Castro JM, Marquez JR, et al. (2016). Clinical manifestations of colorectal cancer patients from a large multi-center study in Colombia. Medicine (Baltimore). 95(4): e4883. https://doi.org/10.1097/md.0000000000004883.

[6] de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, et al. (2010). Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol. 17(4): 1010-1023. https://doi.org/10.1245/10434-009-0887-5.

[7] Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019). Colorectal cancer. Lancet. 394(10207): 1467-1480. https://doi.org/10.1016/s0140-6736(19)32319-0.

[8] Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C (2014). Tumor markers in colorectal cancer, gastric cancer, and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 134(11): 2513. https://doi.org/10.1002/ijc.28384.

[9] Gan N, Jia L, Zheng L (2011). A sandwich electrochemical immunosensor using magnetic DNA nanoprobes for carcinoembryonic antigen. Int J Mol Sci. 12(11): 7410-23. https://dx.doi.org/10.3390%2Fijms12117410.

[10] Hermunen K, Lantto E, Poussa T, Haglund C, Österlund P (2018). Can carcinoembryonic antigen replace Computed tomography in response evaluation of metastatic colorectal cancer?. Acta Oncologica. 57(6): 750-758. https://doi.org/10.1080/0284186X.2018.1431400.

[11] Japaries W (2012). Buku Ajar Onkologi Klinis Edisi 2. Jakarta: EGC.

[12] Sayuti MN (2019). Adenokarsinoma kolo-rektal. Jurnal Averrous. 5(2): 76-82.

[13] Yu P, Zhou M, Qu J, Fu L, Li X, Cai R, Jine B, et al. (2018). The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients. BMC Cancer. 18(1): 1076. https://doi.org/10.1186/s12885-018-4987-0.